◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY
Crinetics Pharmaceuticals, Inc. (CRNX) Revenue 2022–2025
DATA UPDATED 2026-07-16
Crinetics Pharmaceuticals, Inc. annual revenue for fiscal 2025 was $8 million, an increase of 670.0% from $1 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
CRNX Annual Revenue
| Revenue (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|
| Total Revenue | $8M | $1M | $4M | $5M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
CRNX Quarterly Revenue
| Revenue (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|
| Total Revenue | $11M | $6M | $0M | $1M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More CRNX metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow
All CRNX financial statements → Interactive CRNX charts →
About TickerBase · Data methodology & sources
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.